ALT vs ELVN vs PRAX vs CRL vs IQV

For growth investors, Altimmune, Inc.

(ALT) is the stronger pick with 105. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Altimmune, Inc. (ALT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, IQVIA Holdings Inc.

is actually cheaper at 14. 0x.

Over the past 5 years, Enliven Therapeutics, Inc.

(ELVN) delivered a total return of +46. 6%, compared to -76. 4% for Altimmune, Inc. (ALT). Over 10 years, the gap is even starker: ALT returned +1213% versus ELVN's -32. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Enliven Therapeutics, Inc.

(ELVN) is the lower-risk stock at 1. 23β versus Charles River Laboratories International, Inc. 's 1. 44β — meaning CRL is approximately 17% more volatile than ELVN relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Altimmune, Inc.

(ALT) is pulling ahead at 105. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Altimmune, Inc. grew EPS 25. 4% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

IQVIA Holdings Inc.

(IQV) is the more profitable company, earning 8. 3% net margin versus -2148. 6% for Altimmune, Inc. — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IQV leads at 14. 0% versus -2304. 6% for ALT. At the gross margin level — before operating expenses — CRL leads at 30. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 0x forward P/E versus 16. 0x for Charles River Laboratories International, Inc. — 2. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALT: 264. 1% to $11. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Altimmune, Inc.

(ALT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1213% 10Y return). Both have compounded well over 10 years (ALT: +1213%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ALT is a small-cap high-growth stock; ELVN is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.